Affordable Access

Publisher Website

Amphiregulin

Authors
  • Berasain, Carmen
  • Avila, Matías A.1, 2
  • 1 Division of Hepatology and Gene Therapy, CIMA, University of Navarra
  • 2 CIBERehd, Clinica Universidad de Navarra
Type
Published Article
Journal
Seminars in Cell & Developmental Biology
Publisher
Elsevier BV
Publication Date
Jan 01, 2014
Identifiers
DOI: 10.1111/liv.12337
Source
Elsevier
Keywords
License
Unknown

Abstract

Amphiregulin (AREG) is a ligand of the epidermal growth factor receptor (EGFR), a widely expressed transmembrane tyrosine kinase. AREG is synthesized as a membrane-anchored precursor protein that can engage in juxtacrine signaling on adjacent cells. Alternatively, after proteolytic processing by cell membrane proteases, mainly TACE/ADAM17, AREG is secreted and behaves as an autocrine or paracrine factor. AREG gene expression and release is induced by a plethora of stimuli including inflammatory lipids, cytokines, hormones, growth factors and xenobiotics. Through EGFR binding AREG activates major intracellular signaling cascades governing cell survival, proliferation and motility. Physiologically, AREG plays an important role in the development and maturation of mammary glands, bone tissue and oocytes. Chronic elevation of AREG expression is increasingly associated with different pathological conditions, mostly of inflammatory and/or neoplastic nature. Here we review the essential aspects of AREG structure, function and regulation, discuss the basis for its differential role within the EGFR family of ligands, and identify emerging aspects in AREG research with translational potential.

Report this publication

Statistics

Seen <100 times